Introduction {#Sec1}
============

The patient global assessment (global assessment) of disease activity is a crucial component of validated disease activity scores, response criteria, and the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) definition of remission in rheumatoid arthritis (RA). Patients rate their global assessment on a visual analog scale (VAS) by answering the question, "Considering all of the ways your disease affects you, how well are you doing in the past week?" Hence, the patient global not only assesses disease from the patient perspective but also encompasses various factors affecting patients in addition to RA.

Many studies have shown that pain is the strongest factor driving the patient global assessment \[[@CR1]--[@CR5]\]. Several studies have shown that depression affects the patient global assessment, although extensive study has not been done to determine the effect of other psychological factors \[[@CR1], [@CR3], [@CR6]--[@CR8]\]. Depression and other psychological factors might influence patients' assessments of their disease activity; hence, further work is necessary to determine the various biomedical and biopsychosocial factors underlying the patient global assessment.

Recent work has revealed that 30% of patients with RA suffer from persistent undifferentiated symptoms of pain, fatigue, and functional disability despite seeming attainment of low inflammatory disease activity \[[@CR9]\]. This discordance in assessments of disease activity between patients and their providers is a critical issue, so addressing factors that influence patients' assessments of disease activity is necessary to narrow this gap and improve patient outcomes. The purpose of this study was to identify the underlying latent factors driving the patient global assessment using a quantitative, multivariable data reduction approach.

Methods {#Sec2}
=======

Study Design and Populations {#Sec3}
----------------------------

A prospective cross-sectional study was conducted at Mayo Clinic in Rochester, Minnesota. A total of 70 consecutive patients were recruited from our outpatient rheumatology practice with a clinical diagnosis of RA fulfilling the ACR/EULAR 2010 classification criteria \[[@CR10]\]. Eligibility required age to be at least 18 years, residence within 150 miles of the clinic, at least two outpatient follow-up appointments in the prior 18 months, and the most recent appointment within 4 weeks preceding study enrollment. Enrollment was stratified into two groups: one with patient-provider discordance (i.e., at least 25-mm absolute difference between the patient and provider global assessments, which has been used as a clinically important difference by a previous study \[[@CR11]\]), and the other with patient-provider concordance (less than 25-mm absolute difference between the patient and provider global assessments). Recruitment of the group with patient-provider concordance was stratified to include 10 patients with low disease activity and 10 with moderate to high disease activity. The Mayo Clinic Institutional Review Board (IRB) approved the study. All patients provided written informed consent.

Data Collection {#Sec4}
---------------

Data were collected from the electronic medical records for the most recent rheumatologic visit prior to the research study visit, including patient demographics, patient and provider global assessment of disease activity (0--100), tender and swollen joint counts (0--28), inflammatory markers (i.e., erythrocyte sedimentation rate, C-reactive protein), use of traditional and biologic disease-modifying antirheumatic drugs (DMARDs), use of anxiolytics or antidepressants, opioids, fibromyalgia pain medications, and sleep aids. All prior medical records were used to abstract data including the duration of rheumatoid arthritis, clinical diagnosis of comorbidities like anxiety, depression, fibromyalgia, osteoarthritis, and radiographic evidence of joint erosions in hands and feet, serologies for rheumatoid factor (RF) and anti-cyclic citrullinated antibodies (anti-CCP).

Patient-Reported Outcomes (PROs) {#Sec5}
--------------------------------

All participants completed several questionnaires at a research study visit, which included physical and psychological domains. Physical domains included the pain VAS, Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2), Health Assessment Questionnaire-II (HAQ-II), Fibromyalgia Research Survey, and Bristol Rheumatoid Arthritis Fatigue (BRAF) score. SF-MPQ-2 consists of 15 pain descriptors, including six continuous (e.g., aching or throbbing), six intermittent (e.g., stabbing or piercing), six neuropathic (e.g., hot-burning or numbness), and four affective (e.g., punishing or cruel, fearful), which are rated on an intensity scale of 0--3 \[[@CR12], [@CR13]\]. Five pain scores are derived from the sum of the intensity rank values of the words chosen for continuous, intermittent, neuropathic, affective, and total descriptors. HAQ-II is a widely used, reliable, and valid 10-item questionnaire that measures functional status \[[@CR14]\]. The Fibromyalgia Research Survey includes the Widespread Pain Index (WPI) and Symptom Severity (SS). WPI is a measure of the number of painful body regions, and the SS score enables assessment of key somatic domains, including fatigue, unrefreshing sleep, concentration, and other somatic symptoms in persons with current or previous fibromyalgia \[[@CR15]\]. The polysymptomatic distress scale (PSD), the sum of the WPI and SS, characterizes "fibromyalgia-ness" on a continuous scale \[[@CR16]\]. The BRAF score assesses numeric rating scales for fatigue severity, effect, and coping during the past 7 days. All three dimensions are rated from 0 to 10, and the total score is obtained by dividing the sum of individual scores by 3 \[[@CR17]\].

Psychological domains included the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder (GAD-7), Mindfulness Attention and Awareness Scale (MAAS), and several Patient-Reported Outcome Measure Information System (PROMIS) forms. PHQ-9 is a reliable and valid measure of depression severity that scores each of the nine DSM-IV criteria as 0 (not at all) to 3 (nearly every day) \[[@CR18]\]. The IRB-approved protocol required that patients with PHQ-9 scores of at least 10 be evaluated by the investigator and given the option of psychiatry referral. GAD-7 is a seven-item scale used to measure generalized anxiety symptoms. Each item is rated from 0 to 3 ("not at all" to "nearly every day") and all the item scores are added to get the total score \[[@CR19]\]. MAAS is a 15-item scale designed to assess core characteristics of dispositional mindfulness and attention. The scale shows strong psychometric properties and taps a unique quality of consciousness that is related to and predictive of a variety of self-regulation and well-being constructs \[[@CR20]\]. The PROMIS short forms for pain interference (version 1.0); sleep disturbance (version 1.0); fatigue (version 1.0), and ability to participate in social roles and activities (version 2.0) were assessed. Each of the PROMIS instruments has eight items, rated by the patients as 1--5, and total scores are obtained for each of the four instruments separately.

Statistical Methods {#Sec6}
-------------------

Data were evaluated using exploratory factor analysis as a data reduction method to determine the latent constructs in the data. Linear regression models were then used to determine the variability in the patient global assessment explained by the factor scores. A heat map was used to depict the factor loadings. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria).

Results {#Sec7}
=======

The study included a total of 70 patients with mean (SD) age of 61.0 (13.6) years, and 73% were female (Table [1](#Tab1){ref-type="table"}). Nearly all of the patients were non-Hispanic white (99%). The mean (SD) disease duration was 8.0 (6.7) years. Overall, 53% were RF and/or anti-CCP positive. The mean (SD) for the patient global assessment was 44.3 (22.6) and for the provider global assessment was 20.1 (17.7). Among the group of 50 patients with patient-provider discordance, 46 patients had positive discordance (i.e., patient global assessment at least 25 mm higher the provider global assessment); the remaining four patients had negative discordance (i.e., patient global assessment more than 25 mm lower than the patient global assessment). The remaining 20 patients had patient-provider concordance.Table 1Characteristics of 20 concordant and 50 discordant study subjectsCharacteristicConcordant\
(*n* = 20)Discordant\
(*n* = 50)*p* valueAge, years, mean (SD)56.4 (13.7)62.8 (13.3)0.09Sex, female14 (70%)37 (74%)0.73Race, non-Hispanic white18 (90%)49 (98%)0.14Disease duration, years, mean (SD)7.8 (5.1)8.1 (7.3)0.70Time from clinical visit to study visit, days, mean (SD)21.5 (14.4)17.6 (6.1)0.11Disease assessments Patient global (0--100 mm)16 (6, 48)52 (43, 62)\<0.001 Provider global (0--100 mm)22 (5, 50)12 (10, 250.36 Pain (0--100 mm)22 (10, 62)57 (42, 71)0.003 DAS28-CRP2.0 (1.8, 3.4)3.1 (2.5, 3.5)0.14 HAQ disability index, mean (SD)0.5 (0.5)0.9 (0.6)0.009Laboratory assessments CRP, mg/L\<3.0 (\<3.0, 4.5)\<3.0 (\<3.0, 5.8)0.72 RF, positive14 (70%)22 (45%)0.07 ACPA, positive11 (65%)22 (49%)0.26Medication use Prednisone6 (30%)19 (38%)0.53 cDMARD19 (95%)43 (86%)0.28 bDMARD4 (20%)17 (34%)0.25Change of RA medication or dosage at most recent clinical visit5 (25%)6 (12%)0.18Values are number (%), unless otherwise specified*RF* rheumatoid factor, *ACPA* anti-cyclic citrullinated peptide antibody, *DAS28*-*CRP* disease activity score in 28 joints using C-reactive protein, *CRP* C-reactive protein, *cDMARD* conventional disease-modifying antirheumatic drug, *bDMARD* biologic disease-modifying antirheumatic drug

The analysis yielded eight latent factors underlying the patient global assessment (Fig. [1](#Fig1){ref-type="fig"}). Factor 1 included the SF-MPQ (total, sensory and affective) scores, SF-MPQ current pain intensity, pain VAS, and PROMIS pain interference, clearly representing pain as a complex domain. Factor 2 comprised PROMIS fatigue and the BRAF, clearly representing fatigue. Anxiousness by the GAD-7 and depressed mood symptoms by the PHQ-9 scores were strong components of factor 3, while clinical diagnoses of anxiety and depression dominated in factor 4, notably separate from the patient-reported measures of these domains. Aging and presence of osteoarthritis defined factor 5. Clinical diagnosis of fibromyalgia and fibromyalgia research survey WPI were strong components in factor 7.Fig. 1Factor analysis of rheumatoid arthritis disease characteristics, associated comorbidities, and patient-reported outcomes in rheumatoid arthritis. *Dark colored blocks* in each column indicate the strongest characteristics in each principal component. *Blue color* indicates positive loading and *orange* indicates negative loading. *Factor 1* pain; *Factor 2* fatigue; *Factor 3* psychological distress; *Factor 4* depression and anxiety by clinical diagnosis; *Factor 5* advanced age and degenerative arthritis; *Factor 6* inability to participate; *Factor 7* fibromyalgia (Widespread Pain Index and clinical diagnosis); *Factor 8* unknown

PROMIS ability to participate in social roles and activities was a strongly negative component in factor 6, which makes sense as high scores indicate better health and low scores indicate poor health. This score was also a strongly negative component of factor 1, which included other measures of pain. MAAS was a strong negative component of factor 3, which again makes sense as high MAAS scores indicate more mindfulness and factor 3 appears to measure psychological distress. However, body mass index was a strong negative component of factor 4, which is unclear because factor 4 contains clinical diagnoses of depression and anxiety. There were no strong factors (i.e., loadings greater than 0.4) identified in factor 8. The strongest loading of factor 8 was the affective score of the SF-MPQ (loading = 0.36). All eight factors together explained 58% of the variability in the RA disease characteristics, associated comorbidities, and PROs evaluated. The first factor explained 17% and the last factor explained only 2% of the variance in the patient global assessment.

Linear regression analysis showed that the factors representing fibromyalgia (factor 7), inability to participate in social roles and activities (factor 6), and pain (factor 1) showed the greatest correlation with patient global assessment followed by psychological distress (factor 3) and advanced age and degenerative arthritis (factor 5) (Table [2](#Tab2){ref-type="table"}). Of note, fatigue and clinical diagnoses of depression or anxiety were not significantly associated with patient global assessment. Univariable modeling showed that fibromyalgia explained the greatest variability in the patient global assessment (adjusted *R* ^2^ = 0.077). Multivariable analysis showed that the factors altogether explained 28% of the variability in the patient global assessment.Table 2Univariable and multivariable associations between identified latent factors and the patient global assessment in 70 patients with rheumatoid arthritisFactorUnivariable modelsMultivariable model\*Coefficient (SE)*p* valueAdjusted *R* ^2^Coefficient (SE)*p* valueFactor 1: pain6.34 (2.88)0.0320.0636.67 (2441)0.011Factor 2: fatigue2.20 (2.94)0.460.02.81 (2.49)0.26Factor 3: psychological distress4.10 (2.69)0.130.0224.49 (2.32)0.059Factor 4: depression and anxiety (by clinical diagnosis)0.44 (2.70)0.870.00.75 (2.28)0.74Factor 5: advanced age and degenerative arthritis4.67 (2.94)0.120.0264.62 (2.52)0.073Factor 6: inability to participate6.50 (2.76)0.0220.0746.19 (2.44)0.014Factor 7: fibromyalgia6.14 (2.56)0.0200.0775.78 (2.27)0.014Factor 8: unknown−3.57 (2.88)0.220.009−3.54 (2.46)0.16*SE* standard error\* Adjusted *R* ^2^ = 0.28

Discussion {#Sec8}
==========

The patient global assessment is a crucial and widely used measure of disease activity for RA. This study is the first to identify latent factors driving the patient global assessment using factor analysis. Pain, psychological distress, advanced age and degenerative arthritis, inability to participate, and fibromyalgia are key drivers of patient global assessment in patients with RA. These factors altogether explained 28% of the variability in the patient global assessment.

Several studies showed that pain is the strongest correlate of the patient global assessment \[[@CR1]--[@CR5]\]. It was the second most important factor underlying the patient global assessment in our study following fibromyalgia. However, fibromyalgia and other coexisting conditions have a substantial influence on patients' perceptions of pain. These findings highlight pain as a major factor affecting the patients' perceptions of disease activity. Our study also found that other physical domains like degenerative arthritis and advanced age significantly affected patient global assessment.

Studies have shown that depression can influence patients' assessment of disease activity \[[@CR1], [@CR3], [@CR6]--[@CR8]\]. Our study also showed that psychological distress (symptoms of anxiety and depression) affected patient global assessment. Psychological distress might measure the emotional significance of the disease better than clinical diagnosis of depression or anxiety \[[@CR21]\]. We also found that clinical diagnosis of anxiety and/or depression affected patient global assessment similar to some previous studies \[[@CR1], [@CR3], [@CR6]--[@CR8]\]. In addition, inability to participate in social roles and activities also affected the patient global assessment.

Limitations of our study include its limited sample size and the inherent limitations of the patient global assessment measured by VAS, as patients tend to perceive their disease activity on the basis of associated comorbidities and not just RA \[[@CR21]\]. Patients answered numerous questionnaires, which were time-consuming, so we cannot rule out bias due to questionnaire burden.

Conclusions {#Sec9}
===========

The results of this study suggest that rheumatologists should take into consideration all of the identified drivers of patient global assessment when managing patients with RA. Systematic assessment of these domains using validated patient-reported outcome measures could improve shared decision-making and outcomes of RA. Future studies are necessary to determine how to efficiently and effectively measure these factors in routine practice settings. Evidenced-based approaches are needed targeting specific domains to improve patients' quality of life and functional status. These efforts are anticipated to improve communication between patients and providers and optimize disease outcomes.
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